首页 > 最新文献

Current Rheumatology Reports最新文献

英文 中文
Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives. 抗磷脂抗体阳性受试者凝血酶原生成测定作为个性化血栓风险评估:技术现状与展望。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-19 DOI: 10.1007/s11926-024-01140-1
Thomas Foret, Virginie Dufrost, Jeremy Lagrange, Patricia Costa, Guillaume Mourey, Thomas Lecompte, Nadine Magy-Bertrand, Veronique Regnault, Stéphane Zuily, Denis Wahl

Purpose of the review: Thrombotic risk assessment in antiphospholipid positive (aPL +) subjects is a major challenge, and the study of in vitro thrombin generation (thrombin generation assays (TGA)) could provide useful information. Activated protein C (APC) sensitivity is involved in thrombotic events in antiphospholipid syndrome patients. We summarized methods used to assess APC sensitivity with TGA and evaluated the prognostic role of APC resistance through literature search.

Recent findings: APC resistance induced by aPL is a complex pathway. Several cross-sectional studies assessed APC sensitivity to understand thrombotic event mechanisms in aPL + subjects. Only one prospective cohort had investigated the prognostic impact of APC resistance in aPL + subjects, with a positive and significant correlation between APC sensitivity and the risk of thrombosis during the follow up (hazard ratio, 6.07 [95% CI, 1.69-21.87]). APC resistance assessed with TGA could be associated with thrombotic events in aPL + subjects.

综述的目的:抗磷脂阳性(aPL +)患者血栓风险评估是一项重大挑战,体外凝血酶生成研究(凝血酶生成测定(TGA))可提供有用的信息。活化蛋白 C(APC)敏感性与抗磷脂综合征患者的血栓事件有关。我们总结了用 TGA 评估 APC 敏感性的方法,并通过文献检索评估了 APC 抗性的预后作用:由 aPL 诱导的 APC 抗性是一个复杂的途径。一些横断面研究评估了 APC 敏感性,以了解 aPL + 受试者的血栓事件机制。只有一项前瞻性队列研究调查了 aPL + 受试者的 APC 耐药性对预后的影响,结果发现 APC 敏感性与随访期间的血栓形成风险呈显著正相关(危险比为 6.07 [95% CI, 1.69-21.87])。用 TGA 评估的 APC 抗性可能与 aPL + 受试者的血栓事件有关。
{"title":"Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives.","authors":"Thomas Foret, Virginie Dufrost, Jeremy Lagrange, Patricia Costa, Guillaume Mourey, Thomas Lecompte, Nadine Magy-Bertrand, Veronique Regnault, Stéphane Zuily, Denis Wahl","doi":"10.1007/s11926-024-01140-1","DOIUrl":"10.1007/s11926-024-01140-1","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Thrombotic risk assessment in antiphospholipid positive (aPL +) subjects is a major challenge, and the study of in vitro thrombin generation (thrombin generation assays (TGA)) could provide useful information. Activated protein C (APC) sensitivity is involved in thrombotic events in antiphospholipid syndrome patients. We summarized methods used to assess APC sensitivity with TGA and evaluated the prognostic role of APC resistance through literature search.</p><p><strong>Recent findings: </strong>APC resistance induced by aPL is a complex pathway. Several cross-sectional studies assessed APC sensitivity to understand thrombotic event mechanisms in aPL + subjects. Only one prospective cohort had investigated the prognostic impact of APC resistance in aPL + subjects, with a positive and significant correlation between APC sensitivity and the risk of thrombosis during the follow up (hazard ratio, 6.07 [95% CI, 1.69-21.87]). APC resistance assessed with TGA could be associated with thrombotic events in aPL + subjects.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139899479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings). 轴性脊柱关节炎患者减量和停用生物 DMARDs:叙述性综述》(2023 SPARTAN 年会论文集)。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-05-01 Epub Date: 2024-02-09 DOI: 10.1007/s11926-024-01137-w
Haseeb Chaudhary, Mohamad Bittar, Ansaam Daoud, Marina Magrey

Purpose of review: Limited data is available for tapering or discontinuation of biologic therapy in patients with axSpA who are in disease remission. The current review concentrates on published studies regarding dose tapering or withdrawal of biologics in axSpA.

Recent findings: Recent evidence in light of randomized controlled trials suggests that tapering of b-DMARDs is a feasible strategy to maintain remission or low disease activity in axSpA patients. TNF inhibitors were the studied biologics in most of these trials. The disease flare rates were comparable to those maintained on standard dose in most of these studies, although with variable tapering strategies and follow-up. Additionally, the duration of disease in remission prior to tapering, studied primary outcome, and flare definitions were heterogeneous. Female sex, HLA-B*27 negativity, high physician global score, and high CRP were negative predictors of successful tapering, but not consistently reported in all the trials. Although designed to address efficacy, there were no safety concerns with b-DMARD tapering. Withdrawal or complete discontinuation of biologics met with increased risk of flares compared to standard dosing. Tapering of TNF inhibitors may be feasible in certain axSpA patients with an acceptable disease state; however, discontinuation is not currently recommended owing to increased risk of flare. Future studies with axSpA patients with longer remission duration prior to taper and different doses and types of b-DMARDs may provide more guidance.

综述目的:关于疾病缓解期 axSpA 患者减量或停用生物制剂治疗的数据有限。目前的综述主要集中于已发表的关于减量或停用生物制剂治疗 axSpA 的研究:随机对照试验的最新证据表明,减量使用 b-DMARDs 是维持 axSpA 患者病情缓解或低疾病活动性的可行策略。在大多数试验中,TNF抑制剂是研究的生物制剂。在这些研究中,尽管减量策略和随访情况各不相同,但疾病复发率与使用标准剂量时的复发率相当。此外,减量前疾病缓解的持续时间、研究的主要结果和疾病复发的定义也不尽相同。女性性别、HLA-B*27 阴性、医生综合评分高和 CRP 高是成功减量的负面预测因素,但并非所有试验都报告了这一点。尽管试验旨在解决疗效问题,但 b-DMARD 药物减量并不存在安全性问题。与标准剂量相比,停用或完全停用生物制剂会增加复发风险。对于某些疾病状态尚可的 axSpA 患者,减量 TNF 抑制剂可能是可行的;但由于复发风险增加,目前不建议停药。未来针对减量前缓解持续时间较长的 axSpA 患者以及不同剂量和类型的 b-DMARDs 的研究可能会提供更多指导。
{"title":"Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings).","authors":"Haseeb Chaudhary, Mohamad Bittar, Ansaam Daoud, Marina Magrey","doi":"10.1007/s11926-024-01137-w","DOIUrl":"10.1007/s11926-024-01137-w","url":null,"abstract":"<p><strong>Purpose of review: </strong>Limited data is available for tapering or discontinuation of biologic therapy in patients with axSpA who are in disease remission. The current review concentrates on published studies regarding dose tapering or withdrawal of biologics in axSpA.</p><p><strong>Recent findings: </strong>Recent evidence in light of randomized controlled trials suggests that tapering of b-DMARDs is a feasible strategy to maintain remission or low disease activity in axSpA patients. TNF inhibitors were the studied biologics in most of these trials. The disease flare rates were comparable to those maintained on standard dose in most of these studies, although with variable tapering strategies and follow-up. Additionally, the duration of disease in remission prior to tapering, studied primary outcome, and flare definitions were heterogeneous. Female sex, HLA-B*27 negativity, high physician global score, and high CRP were negative predictors of successful tapering, but not consistently reported in all the trials. Although designed to address efficacy, there were no safety concerns with b-DMARD tapering. Withdrawal or complete discontinuation of biologics met with increased risk of flares compared to standard dosing. Tapering of TNF inhibitors may be feasible in certain axSpA patients with an acceptable disease state; however, discontinuation is not currently recommended owing to increased risk of flare. Future studies with axSpA patients with longer remission duration prior to taper and different doses and types of b-DMARDs may provide more guidance.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11062993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current perspective on infections and mitigation strategies in primary systemic vasculitis. 目前对原发性系统性血管炎感染和缓解策略的看法。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-26 DOI: 10.1007/s11926-024-01149-6
Manuel Carpio Tumba, Raisa Lomanto Silva, Ana B Arevalo, S. Sattui
{"title":"Current perspective on infections and mitigation strategies in primary systemic vasculitis.","authors":"Manuel Carpio Tumba, Raisa Lomanto Silva, Ana B Arevalo, S. Sattui","doi":"10.1007/s11926-024-01149-6","DOIUrl":"https://doi.org/10.1007/s11926-024-01149-6","url":null,"abstract":"","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140653095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know? 重症监护病房收治的抗磷脂患者:风湿病医生必须知道什么?
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-23 DOI: 10.1007/s11926-024-01148-7
Q. Moyon, A. Mathian, M. Papo, Alain Combes, Zahir Amoura, M. Pineton de Chambrun
{"title":"Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?","authors":"Q. Moyon, A. Mathian, M. Papo, Alain Combes, Zahir Amoura, M. Pineton de Chambrun","doi":"10.1007/s11926-024-01148-7","DOIUrl":"https://doi.org/10.1007/s11926-024-01148-7","url":null,"abstract":"","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140672264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding the Intricacies of Statin-Associated Muscle Symptoms 解密他汀类药物相关肌肉症状的复杂性
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-05 DOI: 10.1007/s11926-024-01143-y
Tara Fallah Rastegar, Imtiaz Ahmed Khan, Lisa Christopher-Stine

Purpose of Review

Hyperlipidemia is the major cardiovascular morbidity and mortality risk factor. Statins are the first-line treatment for hyperlipidemia. Statin-associated muscle symptoms (SAMS) are the main reason for the discontinuation of statins among patients. The purpose of this review is to guide clinicians to recognize the difference between self-limited and autoimmune statin myopathy in addition to the factors that potentiate them. Finally, treatment strategies will be discussed. This review mostly focuses on new data in the past 3 years.

Recent Findings

Recent findings suggest that SAMS is a complex and multifactorial condition that involves mitochondrial dysfunction, oxidative stress, and immune-mediated mechanisms. Effective management of SAMS requires a thorough evaluation of the patient’s symptoms, risk factors, and medication history, as well as consideration of alternative treatment options.

Summary

While statins are effective in reducing the risk of cardiovascular events, their use is associated with a range of adverse effects, including SAMS.

综述目的高脂血症是心血管疾病发病和死亡的主要风险因素。他汀类药物是治疗高脂血症的一线药物。他汀类药物相关肌肉症状(SAMS)是患者停用他汀类药物的主要原因。本综述旨在指导临床医生认识自限性他汀类药物肌病和自身免疫性他汀类药物肌病之间的区别,以及诱发这两种肌病的因素。最后还将讨论治疗策略。最新研究结果最新研究结果表明,SAMS 是一种复杂的多因素疾病,涉及线粒体功能障碍、氧化应激和免疫介导机制。有效治疗 SAMS 需要对患者的症状、风险因素和用药史进行全面评估,并考虑其他治疗方案。摘要虽然他汀类药物能有效降低心血管事件的风险,但其使用与一系列不良反应有关,包括 SAMS。
{"title":"Decoding the Intricacies of Statin-Associated Muscle Symptoms","authors":"Tara Fallah Rastegar, Imtiaz Ahmed Khan, Lisa Christopher-Stine","doi":"10.1007/s11926-024-01143-y","DOIUrl":"https://doi.org/10.1007/s11926-024-01143-y","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Hyperlipidemia is the major cardiovascular morbidity and mortality risk factor. Statins are the first-line treatment for hyperlipidemia. Statin-associated muscle symptoms (SAMS) are the main reason for the discontinuation of statins among patients. The purpose of this review is to guide clinicians to recognize the difference between self-limited and autoimmune statin myopathy in addition to the factors that potentiate them. Finally, treatment strategies will be discussed. This review mostly focuses on new data in the past 3 years.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Recent findings suggest that SAMS is a complex and multifactorial condition that involves mitochondrial dysfunction, oxidative stress, and immune-mediated mechanisms. Effective management of SAMS requires a thorough evaluation of the patient’s symptoms, risk factors, and medication history, as well as consideration of alternative treatment options.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>While statins are effective in reducing the risk of cardiovascular events, their use is associated with a range of adverse effects, including SAMS.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140580469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AA Amyloidosis: A Contemporary View AA 淀粉样变性:当代视角
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-03 DOI: 10.1007/s11926-024-01147-8

Abstract

Purpose of Review

Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis.

Recent Findings

The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents.

Summary

The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed.

摘要 综述目的 淀粉样蛋白 A(AA)淀粉样变性是慢性炎症性疾病的一种危及器官或生命的并发症。在此,我们回顾了 AA 淀粉样变性的流行病学、病因、发病机制、临床特征以及诊断和治疗策略。 最新发现 由于对潜在疾病的治疗有所改善,AA 淀粉样变性的发病率有所下降。组织病理学检查是诊断的金标准,但磁共振成像可用于检测心脏受累情况。目前还没有清除淀粉样纤维沉积物的治疗方案,因此,治疗策略主要是降低血清淀粉样蛋白 A。抗炎生物制剂极大地丰富了我们的治疗手段。肾衰竭患者首选肾移植,随着移植受者开始从新药中获益,淀粉样变性在异体移植中复发的情况已变得罕见。 小结 近年来,由于出现了旨在控制炎症活动的新疗法,AA 淀粉样变性的治疗方法发生了很大变化。但仍需要能够清除组织中淀粉样沉积物的新药。
{"title":"AA Amyloidosis: A Contemporary View","authors":"","doi":"10.1007/s11926-024-01147-8","DOIUrl":"https://doi.org/10.1007/s11926-024-01147-8","url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Purpose of Review</h3> <p>Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic and therapeutic strategies of AA amyloidosis.</p> </span> <span> <h3>Recent Findings</h3> <p>The incidence of AA amyloidosis has declined due to better treatment of the underlying diseases. Histopathological examination is the gold standard of diagnosis, but magnetic resonance imaging can be used to detect cardiac involvement. There is yet no treatment option for the clearance of amyloid fibril deposits; therefore, the management strategy primarily aims to reduce serum amyloid A protein. Anti-inflammatory biologic agents have drastically expanded our therapeutic armamentarium. Kidney transplantation is preferred in patients with kidney failure, and the recurrence of amyloidosis in the allograft has become rare as transplant recipients have started to benefit from the new agents.</p> </span> <span> <h3>Summary</h3> <p>The management of AA amyloidosis has been considerably changed over the recent years due to the novel therapeutic options aiming to control inflammatory activity. New agents capable of clearing amyloid deposits from the tissues are still needed.</p> </span>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140580460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding Spondyloarthritis Pathogenesis: The Promise of Single-Cell Profiling. 了解脊柱关节炎的发病机制:单细胞图谱分析的前景。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2024-01-16 DOI: 10.1007/s11926-023-01132-7
Joerg Ermann, Micah Lefton, Kevin Wei, Maria Gutierrez-Arcelus

Purpose of review: Single-cell profiling, either in suspension or within the tissue context, is a rapidly evolving field. The purpose of this review is to outline recent advancements and emerging trends with a specific focus on studies in spondyloarthritis.

Recent findings: The introduction of sequencing-based approaches for the quantification of RNA, protein, or epigenetic modifications at single-cell resolution has provided a major boost to discovery-driven research. Fluorescent flow cytometry, mass cytometry, and image-based cytometry continue to evolve. Spatial transcriptomics and imaging mass cytometry have extended high-dimensional analysis to cells in tissues. Applications in spondyloarthritis include the indexing and functional characterization of cells, discovery of disease-associated cell states, and identification of signatures associated with therapeutic responses. Single-cell TCR-seq has provided evidence for clonal expansion of CD8+ T cells in spondyloarthritis. The use of single-cell profiling approaches in spondyloarthritis research is still in its early stages. Challenges include high cost and limited availability of diseased tissue samples. To harness the full potential of the rapidly expanding technical capabilities, large-scale collaborative efforts are imperative.

综述的目的:悬浮或组织背景下的单细胞图谱分析是一个快速发展的领域。本综述旨在概述最近的进展和新出现的趋势,并特别关注脊柱关节炎的研究:基于测序的单细胞定量 RNA、蛋白质或表观遗传修饰方法的引入极大地推动了以发现为导向的研究。荧光流式细胞术、质控细胞术和基于图像的细胞术不断发展。空间转录组学和成像质量细胞仪将高维分析扩展到了组织中的细胞。在脊柱关节炎中的应用包括对细胞进行索引和功能表征、发现与疾病相关的细胞状态以及识别与治疗反应相关的特征。单细胞 TCR-seq 为脊柱关节炎中 CD8+ T 细胞的克隆扩增提供了证据。单细胞分析方法在脊柱关节炎研究中的应用仍处于早期阶段。面临的挑战包括成本高昂和病变组织样本有限。要充分利用迅速发展的技术能力,大规模的合作势在必行。
{"title":"Understanding Spondyloarthritis Pathogenesis: The Promise of Single-Cell Profiling.","authors":"Joerg Ermann, Micah Lefton, Kevin Wei, Maria Gutierrez-Arcelus","doi":"10.1007/s11926-023-01132-7","DOIUrl":"10.1007/s11926-023-01132-7","url":null,"abstract":"<p><strong>Purpose of review: </strong>Single-cell profiling, either in suspension or within the tissue context, is a rapidly evolving field. The purpose of this review is to outline recent advancements and emerging trends with a specific focus on studies in spondyloarthritis.</p><p><strong>Recent findings: </strong>The introduction of sequencing-based approaches for the quantification of RNA, protein, or epigenetic modifications at single-cell resolution has provided a major boost to discovery-driven research. Fluorescent flow cytometry, mass cytometry, and image-based cytometry continue to evolve. Spatial transcriptomics and imaging mass cytometry have extended high-dimensional analysis to cells in tissues. Applications in spondyloarthritis include the indexing and functional characterization of cells, discovery of disease-associated cell states, and identification of signatures associated with therapeutic responses. Single-cell TCR-seq has provided evidence for clonal expansion of CD8+ T cells in spondyloarthritis. The use of single-cell profiling approaches in spondyloarthritis research is still in its early stages. Challenges include high cost and limited availability of diseased tissue samples. To harness the full potential of the rapidly expanding technical capabilities, large-scale collaborative efforts are imperative.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sequence of Events in the Pathogenesis of Axial Spondyloarthritis: A Current Review-2023 SPARTAN Meeting Proceedings. 轴性脊柱关节炎发病过程中的事件顺序:当前回顾--2023 年 SPARTAN 会议论文集》。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2024-02-07 DOI: 10.1007/s11926-024-01136-x
Archita Srinath, Akihiro Nakamura, Nigil Haroon

Purpose of review: Over the past two decades, significant progress has been made to untangle the etiology of inflammation and new bone formation (NBF) associated with axial spondyloarthritis (axSpA). However, exact mechanisms as to how the disease initiates and develops remain elusive.

Recent findings: Type 3 immunity, centered around the IL-23/IL-17 axis, has been recognized as a key player in the pathogenesis of axSpA. Multiple hypotheses associated with HLA-B*27 have been proposed to account for disease onset and progression of axSpA, potentially by driving downstream T cell responses. However, HLA-B*27 alone is not sufficient to fully explain the development of axSpA. Genome-wide association studies (GWAS) identified several genes that are potentially relevant to disease pathogenesis leading to a better understanding of the immune activation seen in axSpA. Furthermore, gut microbiome studies suggest an altered microbiome in axSpA, and animal studies suggest a pathogenic role for immune cells migrating from the gut to the joint. Recent studies focusing on the pathogenesis of new bone formation (NBF) have highlighted the importance of endochondral ossification, mechanical stress, pre-existing inflammation, and activated anabolic signaling pathways during the development of NBF. Despite the complex etiology of axSpA, recent studies have shed light on pivotal pieces that could lead to a better understanding of the pathogenic events in axSpA.

综述的目的:在过去的二十年中,在揭示与轴性脊柱关节炎(axSpA)相关的炎症和新骨形成(NBF)的病因方面取得了重大进展。然而,关于该疾病如何开始和发展的确切机制仍然难以捉摸:最近的发现:以 IL-23/IL-17 轴为中心的第三类免疫被认为是轴性脊柱关节炎发病机制中的关键因素。与HLA-B*27相关的多种假说已被提出来解释轴性SpA的发病和进展,这些假说可能是通过驱动下游T细胞反应来解释的。然而,仅凭 HLA-B*27 并不足以完全解释 axSpA 的发病原因。全基因组关联研究(GWAS)发现了几个可能与疾病发病机制相关的基因,从而使人们对 axSpA 中的免疫激活有了更好的了解。此外,肠道微生物组研究表明,axSpA 中的微生物组发生了改变,动物研究表明,从肠道迁移到关节的免疫细胞具有致病作用。最近对新骨形成(NBF)发病机制的研究强调了软骨内骨化、机械应力、原有炎症和激活的合成代谢信号通路在新骨形成过程中的重要性。尽管axSpA的病因很复杂,但最近的研究揭示了一些关键环节,有助于更好地了解axSpA的致病事件。
{"title":"Sequence of Events in the Pathogenesis of Axial Spondyloarthritis: A Current Review-2023 SPARTAN Meeting Proceedings.","authors":"Archita Srinath, Akihiro Nakamura, Nigil Haroon","doi":"10.1007/s11926-024-01136-x","DOIUrl":"10.1007/s11926-024-01136-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>Over the past two decades, significant progress has been made to untangle the etiology of inflammation and new bone formation (NBF) associated with axial spondyloarthritis (axSpA). However, exact mechanisms as to how the disease initiates and develops remain elusive.</p><p><strong>Recent findings: </strong>Type 3 immunity, centered around the IL-23/IL-17 axis, has been recognized as a key player in the pathogenesis of axSpA. Multiple hypotheses associated with HLA-B*27 have been proposed to account for disease onset and progression of axSpA, potentially by driving downstream T cell responses. However, HLA-B*27 alone is not sufficient to fully explain the development of axSpA. Genome-wide association studies (GWAS) identified several genes that are potentially relevant to disease pathogenesis leading to a better understanding of the immune activation seen in axSpA. Furthermore, gut microbiome studies suggest an altered microbiome in axSpA, and animal studies suggest a pathogenic role for immune cells migrating from the gut to the joint. Recent studies focusing on the pathogenesis of new bone formation (NBF) have highlighted the importance of endochondral ossification, mechanical stress, pre-existing inflammation, and activated anabolic signaling pathways during the development of NBF. Despite the complex etiology of axSpA, recent studies have shed light on pivotal pieces that could lead to a better understanding of the pathogenic events in axSpA.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139697091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erosive Hand Osteoarthritis: Recent Advances and Future Treatments. 侵蚀性手部骨关节炎:最新进展与未来治疗。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2024-01-12 DOI: 10.1007/s11926-023-01130-9
Marta B Bean, Marta Favero, Roberta Ramonda, Carla R Scanzello

Purpose of the review: Erosive hand osteoarthritis (EHOA) is an aggressive form of hand osteoarthritis that leads to significant disability, and recent data suggests that it is increasing in prevalence. This review provides an update of our current understanding of epidemiology, genetic associations, biomarkers, pathogenesis, and treatment of EHOA, with particular focus on studies published within the last 5 years.

Recent findings: New studies of EHOA have identified new genetic loci associated with disease, including variants in genes involved in inflammation and bone remodeling. Preclinical studies implicate pathways of innate immunity, including some that may be causal in the condition. Recent novel studies showed that inflammatory features identified by ultrasound and MRI are associated with development of erosive lesions over time on conventional radiography. In the future, these imaging modalities may be useful in identifying patients at risk of adverse outcomes. Promising new findings in genetics, biomarkers, and treatment targets will hopefully allow for future therapeutic options for this debilitating condition.

综述的目的:侵蚀性手部骨关节炎(EHOA)是一种侵袭性手部骨关节炎,可导致严重残疾,最近的数据表明其发病率正在上升。本综述介绍了我们目前对 EHOA 的流行病学、遗传关联、生物标志物、发病机制和治疗的最新认识,尤其关注过去 5 年内发表的研究:对 EHOA 的新研究发现了与疾病相关的新基因位点,包括涉及炎症和骨重塑的基因变异。临床前研究发现了先天性免疫的途径,其中一些可能与该病有关。最近的新研究表明,超声波和核磁共振成像发现的炎症特征与传统放射学检查中侵蚀性病变的发展有关。未来,这些成像模式可能有助于识别有不良后果风险的患者。遗传学、生物标志物和治疗靶点方面的新发现有望为这种使人衰弱的疾病提供未来的治疗方案。
{"title":"Erosive Hand Osteoarthritis: Recent Advances and Future Treatments.","authors":"Marta B Bean, Marta Favero, Roberta Ramonda, Carla R Scanzello","doi":"10.1007/s11926-023-01130-9","DOIUrl":"10.1007/s11926-023-01130-9","url":null,"abstract":"<p><strong>Purpose of the review: </strong>Erosive hand osteoarthritis (EHOA) is an aggressive form of hand osteoarthritis that leads to significant disability, and recent data suggests that it is increasing in prevalence. This review provides an update of our current understanding of epidemiology, genetic associations, biomarkers, pathogenesis, and treatment of EHOA, with particular focus on studies published within the last 5 years.</p><p><strong>Recent findings: </strong>New studies of EHOA have identified new genetic loci associated with disease, including variants in genes involved in inflammation and bone remodeling. Preclinical studies implicate pathways of innate immunity, including some that may be causal in the condition. Recent novel studies showed that inflammatory features identified by ultrasound and MRI are associated with development of erosive lesions over time on conventional radiography. In the future, these imaging modalities may be useful in identifying patients at risk of adverse outcomes. Promising new findings in genetics, biomarkers, and treatment targets will hopefully allow for future therapeutic options for this debilitating condition.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Broadening the Scope of Resilience in Chronic Pain: Methods, Social Context, and Development. 拓宽慢性疼痛的复原力范围:方法、社会背景和发展。
IF 5 2区 医学 Q1 Medicine Pub Date : 2024-04-01 Epub Date: 2024-01-25 DOI: 10.1007/s11926-024-01133-0
John A Sturgeon, Caroline Zubieta, Chelsea M Kaplan, Jennifer Pierce, Anne Arewasikporn, P Maxwell Slepian, Afton L Hassett, Zina Trost

Purpose of review: A wellspring of new research has offered varying models of resilience in chronic pain populations; however, resilience is a multifaceted and occasionally nebulous construct. The current review explores definitional and methodological issues in existing observational and clinical studies and offers new directions for future studies of pain resilience.

Recent findings: Definitions of pain resilience have historically relied heavily upon self-report and from relatively narrow scientific domains (e.g., positive psychology) and in narrow demographic groups (i.e., Caucasian, affluent, or highly educated adults). Meta-analytic and systematic reviews have noted moderate overall quality of resilience-focused assessment and treatment in chronic pain, which may be attributable to these narrow definitions. Integration of research from affiliated fields (developmental models, neuroimaging, research on historically underrepresented groups, trauma psychology) has the potential to enrich current models of pain resilience and ultimately improve the empirical and clinical utility of resilience models in chronic pain.

综述的目的:大量新的研究为慢性疼痛人群提供了不同的恢复力模型;然而,恢复力是一个多方面的、有时甚至是模糊的概念。本综述探讨了现有观察性研究和临床研究中的定义和方法问题,并为今后的疼痛复原力研究提供了新的方向:疼痛恢复力的定义历来严重依赖于自我报告,并且来自相对狭窄的科学领域(如积极心理学)和狭窄的人口群体(即白种人、富裕或受过高等教育的成年人)。元分析和系统综述指出,以复原力为重点的慢性疼痛评估和治疗的总体质量一般,这可能与这些狭隘的定义有关。整合相关领域的研究(发展模型、神经影像学、对历史上代表性不足的群体的研究、创伤心理学)有可能丰富目前的疼痛恢复力模型,并最终提高慢性疼痛恢复力模型的实证性和临床实用性。
{"title":"Broadening the Scope of Resilience in Chronic Pain: Methods, Social Context, and Development.","authors":"John A Sturgeon, Caroline Zubieta, Chelsea M Kaplan, Jennifer Pierce, Anne Arewasikporn, P Maxwell Slepian, Afton L Hassett, Zina Trost","doi":"10.1007/s11926-024-01133-0","DOIUrl":"10.1007/s11926-024-01133-0","url":null,"abstract":"<p><strong>Purpose of review: </strong>A wellspring of new research has offered varying models of resilience in chronic pain populations; however, resilience is a multifaceted and occasionally nebulous construct. The current review explores definitional and methodological issues in existing observational and clinical studies and offers new directions for future studies of pain resilience.</p><p><strong>Recent findings: </strong>Definitions of pain resilience have historically relied heavily upon self-report and from relatively narrow scientific domains (e.g., positive psychology) and in narrow demographic groups (i.e., Caucasian, affluent, or highly educated adults). Meta-analytic and systematic reviews have noted moderate overall quality of resilience-focused assessment and treatment in chronic pain, which may be attributable to these narrow definitions. Integration of research from affiliated fields (developmental models, neuroimaging, research on historically underrepresented groups, trauma psychology) has the potential to enrich current models of pain resilience and ultimately improve the empirical and clinical utility of resilience models in chronic pain.</p>","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Rheumatology Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1